These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 18057188)

  • 21. Use of forecasted assessment of quality of life to validate time-trade-off utilities and a prostate cancer screening decision-analytic model.
    Cantor SB; Deshmukh AA; Krahn MD; Volk RJ
    Health Expect; 2015 Oct; 18(5):1610-20. PubMed ID: 26039695
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incorporating feelings related to the uncertainty about future health in utility measurement.
    Gandjour A
    Health Econ; 2008 Oct; 17(10):1207-13. PubMed ID: 18074407
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Towards a better QALY model.
    Abellán-Perpiñán JM; Pinto-Prades JL; Méndez-Martínez I; Badía-Llach X
    Health Econ; 2006 Jul; 15(7):665-76. PubMed ID: 16518836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quality of life utilities for pelvic inflammatory disease health states.
    Smith KJ; Tsevat J; Ness RB; Wiesenfeld HC; Roberts MS
    Sex Transm Dis; 2008 Mar; 35(3):307-11. PubMed ID: 18032995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correcting biases in standard gamble and time tradeoff utilities.
    van Osch SM; Wakker PP; van den Hout WB; Stiggelbout AM
    Med Decis Making; 2004; 24(5):511-7. PubMed ID: 15359000
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lack of multiplicative transitivity in person trade-off responses.
    Schwarzinger M; Lanoë JL; Nord E; Durand-Zaleski I
    Health Econ; 2004 Feb; 13(2):171-81. PubMed ID: 14737754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predicting utility scores for prostate cancer: mapping the Prostate Cancer Index to the Patient-Oriented Prostate Utility Scale (PORPUS).
    Bremner KE; Mitsakakis N; Wilson L; Krahn MD
    Prostate Cancer Prostatic Dis; 2014 Mar; 17(1):47-56. PubMed ID: 24126796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The construction of standard gamble utilities.
    van Osch SM; Stiggelbout AM
    Health Econ; 2008 Jan; 17(1):31-40. PubMed ID: 17410521
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improving decision analyses: parent preferences (utility values) for pediatric health outcomes.
    Carroll AE; Downs SM
    J Pediatr; 2009 Jul; 155(1):21-5, 25.e1-5. PubMed ID: 19394030
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A utility-theoretic approach to the aggregation of willingness to pay measured in decomposed scenarios: development and empirical test.
    Hammerschmidt T; Zeitler HP; Leidl R
    Health Econ; 2004 Apr; 13(4):345-61. PubMed ID: 15067672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer.
    Ferrer M; Suárez JF; Guedea F; Fernández P; Macías V; Mariño A; Hervas A; Herruzo I; Ortiz MJ; Villavicencio H; Craven-Bratle J; Garin O; Aguiló F;
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):421-32. PubMed ID: 18325680
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Joint Utility Estimators in Substance Use Disorders.
    Wittenberg E; Bray JW; Gebremariam A; Aden B; Nosyk B; Schackman BR
    Value Health; 2017 Mar; 20(3):458-465. PubMed ID: 28292491
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Assessment of health related quality of life--part 3--preference based measures].
    Horowitz E; Hassidim H; Abadi-Korek I; Shemer J
    Harefuah; 2008 Nov; 147(11):914-9, 938. PubMed ID: 19264015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pilot study of a utilities-based treatment decision intervention for prostate cancer patients.
    Knight SJ; Nathan DP; Siston AK; Kattan MW; Elstein AS; Collela KM; Wolf MS; Slimack NS; Bennett CL; Golub RM
    Clin Prostate Cancer; 2002 Sep; 1(2):105-14. PubMed ID: 15046701
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An interim determination of health gain from oral cancer and precancer screening: 1. Obtaining health state utilities.
    Downer MC; Jullien JA; Speight PM
    Community Dent Health; 1997 Sep; 14(3):139-42. PubMed ID: 9332037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Watchful waiting and health related quality of life for patients with localized prostate cancer: data from CaPSURE.
    Arredondo SA; Downs TM; Lubeck DP; Pasta DJ; Silva SJ; Wallace KL; Carroll PR
    J Urol; 2008 May; 179(5 Suppl):S14-8. PubMed ID: 18405740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome.
    Speakman M; Khullar V; Mundy A; Odeyemi I; Bolodeoku J
    Curr Med Res Opin; 2008 Aug; 24(8):2173-9. PubMed ID: 18565239
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incorporating model uncertainty in cost-effectiveness analysis: a Bayesian model averaging approach.
    Negrín MA; Vázquez-Polo FJ
    J Health Econ; 2008 Sep; 27(5):1250-9. PubMed ID: 18490067
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of comorbidities upon ocular and systemic health-related quality of life.
    Real FJ; Brown GC; Brown HC; Brown MM
    Br J Ophthalmol; 2008 Jun; 92(6):770-4. PubMed ID: 18420747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.